NY-ADAR-CAPITAL-PARTNERS
Zev Marynberg, Founder and CIO of the hedge fund Adar Macro Fund, one of the top performing hedge funds of 2016 with a 33.5 percent return on investment in 2016, reveals in an interview with Bloomberg his investment strategy for 2017. “We invest mainly in Latin America and Europe. We look for undervalued assets, mainly fixed income securities issued by sovereign or quasi-sovereign issuers, in countries where we believe macroeconomic changes will occur. We perform only fundamental analysis and visit each of the places where we invest. Our main focus is on securities issued or backed by nations or states. A sovereign issuer may have to restructure, but given sufficient resources and time, would be able to repay its debts. Corporations can disappear, as happened with Lehman Brothers. We don’t want to take that risk for our investors” .
Brazil, Colombia and Venezuelan bonds contributed to the fund’s great performance in 2016. Marynberg thinks there are great opportunities in the areas Adar Macro Fund focuses on. “We don’t look for 20 assets; we look for five to ten ideas. Still, some assets are very undervalued and some yields are well above U.S. Treasury yields, with very attractive coupons.”
“In 2017 Adar Macro Fund took profits in Colombia because our investments matured. We added assets in Argentina, since we believe the economy will begin to grow, as well as in Portugal, since some quasi-sovereign fixed-income securities trade with a spread of 400 over sovereign,” says Zev Marynberg.
Concerning its strategy for 2017, Zev Marynberg comments: “In the first place we have a current yield above 8 percent per annum. Some of our investment opportunities may mature sooner rather than later because the macroeconomic indicators in those countries are already improving. You can never predict a day for a capital appreciation to occur, but it’s certain that over time, distortions in undervalued assets will disappear.”
“ We like sovereigns; they are liquid, have good payment capacity and will never disappear, at least not in our lifetimes. In currencies, we like the U.S. dollar. We are optimistic that President Trump is pragmatic, has experience and will take the measures the U.S. economy needs in order to grow more. Over 85 percent of our investment is in the U.S. dollar. We reduced duration in our portfolio since interest rates have only one direction to go, and that’s up,” said Marynberg.
On the rise of populism in Europe, the CIO of Adar Macro Fund stated: “We are overweight in Germany. REITs dedicated to eastern Germany are still trading very cheap, cheaper than the rest of Germany, Europe and even South America. You still can buy the best offer space in Berlin at a discount with respect to Mexico City, Buenos Aires and even Caracas, Venezuela. In Portugal, fixed-income markets still have good opportunities.”
Adar Macro Fund
Adar Macro Fund is a hedge fund managed by Adar Capital Partners. Founded in 2011, Adar Capital Partners Ltd. provides investment advice to institutions, family offices and private equity funds, mainly in Latin America and Europe. It currently manages total assets in excess of $1.5 billion. In 2016 Adar Macro Fund obtained the awards "Best Latin America Emerging Markets Fund 3 Years " by Acquisition International and "Most Innovative Hedge Fund of the Year 2016 " according to the magazine Wealth & Finance. Ticker Bloomberg: ADARMAA KY.
http://www.adarcapitalpartners.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20170310005022/en/
Contact:
Media:
Newsline
Miguel Ramos
mramos@newsline-pr.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CCM Biosciences Announces Presentation of Data on its First-In-Class AML Drug Program at ASCO 202520.5.2025 22:30:00 CEST | Press release
Company’s AML drug program is focused on both newly diagnosed and relapsed/refractory FLT3-positive AML, overcoming major forms of resistance to FDA-approved FLT3 inhibitors, and outperforms other investigational inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its next-generation FLT3 inhibitor drug program for acute myeloid leukemia (AML) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. Acute Myeloid Leukemia (AML) is the most severe form of leukemia with few treatment options, and a malignancy frequently driven by mutations in the FMS-like tyrosine kinase 3 (FLT3) gene. The FLT3 internal tandem duplication (ITD) and tyrosine kinase domain (TKD) mutations, particularly D835 and F691, appear in approximately 30% of AML patients, often leading to poor prognosis and resistance to exi
IonQ Partners with Sweden’s Einride to Develop Quantum Supply Chain and Quantum-Enhanced Logistics for Autonomous Driving Solutions20.5.2025 22:05:00 CEST | Press release
IonQ and Einride will collaborate to develop quantum solutions for fleet routing, logistics optimization, and supply chain solutionsIonQ’s investment will grow its European presence and reinforce commitment to building a quantum economy in Sweden and the European market IonQ (NYSE: IONQ), a leading commercial quantum computing and networking company, today announced an investment partnership with Einride, a leading global freight mobility company that provides digital, electric, and autonomous technology to explore how quantum computing can drive the next generation of fleet optimization and logistics. Together, IonQ and Einride will develop quantum applications that address large-scale routing and scheduling problems that have traditionally challenged classical computing. By combining IonQ’s advanced quantum systems with Einride’s expertise in autonomous fleet logistics, the two companies will work to unlock new levels of efficiency, reliability, and sustainability for the global frei
CCM Biosciences Announces Presentation of Data on its First-In-Class NSCLC Drug Program at ASCO 202520.5.2025 21:26:00 CEST | Press release
Company’s NSCLC drug program is focused on overcoming both mutational and non-mutational resistance to 3rd-generation EGFR inhibitors and outperforms other investigational 4th-generation inhibitors in a wide range of drug resistance models. CCM Biosciences, a diversified pharmaceutical discovery and development company, today announced the upcoming presentation of its 4th-generation EGFR inhibitor drug program for non-small cell lung cancer (NSCLC) at the 2025 Annual Conference of the American Society of Clinical Oncology (ASCO), taking place May 30 to June 3 in Chicago. NSCLC, which accounts for 80% of lung cancer, is the most common cause of cancer death worldwide. Epidermal growth factor receptor (EGFR)-activating mutations (Del19 or L858R) are major oncogenic drivers of NSCLC. EGFR-positive NSCLC accounts for approximately 30% of all diagnosed cases of NSCLC (a similar market size to PD-L1-positive NSCLC, which is addressed by the world’s top-selling drug, Keytruda®). The current s
NielsenIQ's Chief Technology Officer Mohit Kapoor Named Executive of the Year at Global Tech & AI Awards for Leading NIQ’s AI-Driven Tech Transformation20.5.2025 21:24:00 CEST | Press release
NielsenIQ (NIQ) is proud to announce that Mohit Kapoor, Chief Technology Officer, was named Executive of the Year at the inaugural Global Tech & AI Awards. This honor recognizes Mohit's exceptional leadership and visionary contributions to the tech industry, particularly in the realm of AI-powered consumer intelligence. "I am deeply honored to receive the Executive of the Year award at the Global Tech & AI Awards. This recognition is a testament to the incredible work and dedication of the entire NielsenIQ team,” said Mohit Kapoor, Chief Technology Officer, NIQ. “Together, we have redefined consumer and retail intelligence, leveraging AI to deliver unparalleled insights and drive meaningful change in the industry." Under Mohit's leadership, NIQ has adopted an AI-powered approach to its ambitious digital transformation which included a $400 million technology investment and the migration of its global client base onto Discover– a unified, cloud-based platform that seamlessly integrates
Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco20.5.2025 21:08:00 CEST | Press release
As part of the implementation of the commitments made in the joint declaration between His Majesty King Mohammed VI, may God Assist Him, and His Highness Sheikh Mohamed bin Zayed Al Nahyan, TAQA Morocco, in partnership with Nareva and the Mohammed VI Fund for Investment, has signed three memorandums of understanding and related development agreements with the Government of Morocco and ONEE. These agreements cover the development of structuring projects in the power, water and renewable energy sectors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250520313620/en/ Strategic Partnership Between the Government of Morocco and TAQA Morocco, Nareva, ONEE and the Mohammed VI Investment Fund to Develop Key Power and Water Infrastructures in the Kingdom of Morocco (Photo: AETOSWire) The program aims to strengthen the Kingdom's water and energy sovereignty through the development of flexible natural gas-based power generation capacit
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom